Cambridge Investment Research Advisors
MCRB icon

Cambridge Investment Research Advisors’s Seres Therapeutics MCRB Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,242
Closed -$215K – 3219
2023
Q2 		$215K Buy
+2,242
New +$244K ﹤0.01% 2816

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Cambridge Investment Research Advisors's MCRB Position: Q3 2023 in Review

Cambridge Investment Research Advisors sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 2,242 shares — an estimated $215K sold.

Cambridge Investment Research Advisors first reported a position in MCRB in Q2 2023 and held it in 1 quarter. The position peaked at $215K in Q2 2023. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

  • Cambridge Investment Research Advisors reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 2,242 Seres Therapeutics shares in Q3 2023, an estimated $215K.
  • Cambridge Investment Research Advisors first reported a position in Seres Therapeutics in Q2 2023 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Seres Therapeutics position peaked at $215K in Q2 2023.
  • 134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.